Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp. (Nasdaq: KTTA, KTTAW) generates frequent news as a clinical-stage biotechnology company centered on PAS-004, a next-generation macrocyclic oral MEK inhibitor. Coverage of KTTA and KTTAW news often focuses on clinical trial progress in neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), MAPK pathway-driven advanced cancers and ALS, as well as capital markets and regulatory developments that shape the company’s trajectory.
Investors following Pasithea’s news can expect detailed updates on its Phase 1 and Phase 1/1b studies, including safety, pharmacokinetic and pharmacodynamic data, dose-escalation decisions, and early signs of clinical activity such as partial responses or disease control rates in advanced cancer patients. The company also reports on the activation of new clinical trial sites in regions such as the United States, South Korea and Australia for NF1-PN, and on grant-funded initiatives like the Hoffman ALS Clinical Trial Award supporting a Phase 1 PAS-004 study in ALS patients.
Beyond clinical results, Pasithea news includes financing events such as public offerings of common stock and at-the-market programs, with stated uses of proceeds for research, clinical trials, technology development, licensing and potential acquisitions. Regulatory and governance items disclosed through press releases and SEC filings, including proxy proposals, stock incentive plan amendments and responses to Nasdaq listing notices, also feature in the news flow.
For readers tracking KTTA and KTTAW, this news stream offers insight into how Pasithea advances PAS-004 across NF1-PN, oncology and ALS, how it manages its capital structure, and how regulatory milestones may influence its development plans. Regularly reviewing these updates can help contextualize the company’s clinical data, trial timelines and corporate actions over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.
The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.
Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its Chairman, Prof. Lawrence Steinman, will receive the 2023 Pioneer in Medicine Award for significant contributions to brain mapping and therapeutics at the 20th Annual Gathering for the Cure on February 17, 2023. This award is presented by the Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping Foundation, recognizing pioneering work in fields like multiple sclerosis (MS). The company is focusing on developing a proprietary engineered DNA plasmid vaccine, PAS-002, targeting GlialCAM for MS treatment, affecting over 2.3 million people worldwide.